Improvement in Serum Eosinophilia is Observed in Clinical Responders to Ustekinumab but not Adalimumab in Inflammatory Bowel Disease

医学 乌斯特基努马 阿达木单抗 内科学 嗜酸性粒细胞 胃肠病学 炎症性肠病 克罗恩病 结肠镜检查 溃疡性结肠炎 免疫学 疾病 结直肠癌 癌症 哮喘
作者
Emily C L Wong,Parambir S. Dulai,John K. Marshall,Vipul Jairath,Walter Reinisch,Neeraj Narula
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
标识
DOI:10.1093/ecco-jcc/jjaf006
摘要

Abstract Introduction In inflammatory bowel disease (IBD), the number of eosinophils increases in the lamina propria of the intestinal tract, but their specific patho-mechanistic role remains unclear. Elevated blood eosinophil counts in active IBD suggest their potential as biomarkers for predicting response to biologic therapies. This study evaluates blood eosinophil count trends and their predictive value for clinical response and endoscopic improvement in patients with IBD receiving ustekinumab or adalimumab induction therapy. Methods Participant-level data from phase 3 and 4 clinical trials (UNIFI, SEAVUE, VARSITY) evaluating ustekinumab and adalimumab for moderate-severe Crohn's disease (CD) and ulcerative colitis (UC) were used. The primary outcome was clinical response, defined by reductions in disease activity scores. Eosinophil counts were compared between responders and non-responders at multiple time points using t-tests. Logistic regression assessed the odds of achieving a clinical response based on baseline eosinophil counts. Results Among patients treated with ustekinumab for UC, responders had significantly higher baseline eosinophil counts compared to non-responders (0.21 x10^9/L vs. 0.18 x10^9/L, p=0.042). By week 8, responders showed a greater absolute (-0.07 x10^9/L vs. -0.01 x10^9/L, p < 0.001) and percent decline (-33.33% vs. -5.55%, p=0.027) in eosinophil counts. In CD, ustekinumab responders also had higher baseline eosinophil counts and showed significant reductions by week 8. However, no significant differences in eosinophil counts were observed among CD patients treated with adalimumab or UC patients treated with vedolizumab. Conclusion Eosinophil reduction was identified as a marker for early response to ustekinumab in both UC and CD, but not adalimumab. No difference was observed among UC patients treated with vedolizumab either. Targeting the IL-12/IL-23 pathway may be more effective in managing eosinophil-associated inflammation in IBD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
流星雨发布了新的文献求助10
2秒前
forest发布了新的文献求助10
5秒前
Jeffery426完成签到,获得积分10
9秒前
WY完成签到 ,获得积分10
10秒前
baobeikk完成签到 ,获得积分10
14秒前
我就想看看文献完成签到 ,获得积分10
16秒前
Zhou发布了新的文献求助10
17秒前
ylyao完成签到 ,获得积分10
25秒前
林谷雨完成签到 ,获得积分10
30秒前
不吃芹菜完成签到,获得积分10
32秒前
陈炳蓉完成签到,获得积分10
32秒前
xiaowuge完成签到 ,获得积分10
40秒前
刘丰完成签到 ,获得积分10
48秒前
现实的大白完成签到 ,获得积分10
49秒前
cq_2完成签到,获得积分10
49秒前
orixero应助科研通管家采纳,获得10
56秒前
霁昕完成签到 ,获得积分10
1分钟前
光亮若翠完成签到,获得积分10
1分钟前
onevip完成签到,获得积分10
1分钟前
石子完成签到 ,获得积分10
1分钟前
流浪的鲨鱼完成签到,获得积分20
1分钟前
Jasmineyfz完成签到 ,获得积分10
1分钟前
1分钟前
个性的孤风完成签到,获得积分20
1分钟前
ramsey33完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
helinahs完成签到 ,获得积分10
1分钟前
xingxing完成签到 ,获得积分10
1分钟前
YU发布了新的文献求助30
1分钟前
白昼の月完成签到 ,获得积分0
1分钟前
丰富的归尘完成签到 ,获得积分10
1分钟前
forest关注了科研通微信公众号
1分钟前
小慧冲冲冲完成签到,获得积分10
1分钟前
liangguangyuan完成签到 ,获得积分10
2分钟前
逍遥呱呱完成签到 ,获得积分10
2分钟前
谨慎井完成签到,获得积分10
2分钟前
MLJ完成签到 ,获得积分10
2分钟前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3571332
求助须知:如何正确求助?哪些是违规求助? 3141926
关于积分的说明 9444874
捐赠科研通 2843331
什么是DOI,文献DOI怎么找? 1562830
邀请新用户注册赠送积分活动 731326
科研通“疑难数据库(出版商)”最低求助积分说明 718524